This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||VTVT / vTv Therapeutics Inc (918385105)|
|President & CEO||Holcombe Stephen L.|
|Institutional Shares||5,697,347 - 24.67%|
|Common Shares Outstanding2||23,094,221 shares (as of 2018-03-31)|
|Institutional Value||$ 29,108,000 USD|
Institutional Stock Ownership and Shareholders()
vTv Therapeutics Inc (NASDAQ:VTVT) has 49 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,697,347 shares.
Largest shareholders include
GMT Capital Corp, Franklin Resources Inc, Massachusetts Financial Services Co /ma/, Royce & Associates LLC, BlackRock Inc., JP Morgan Chase & Co, FMR LLC / Fidelity, Vanguard Group Inc, Sphera Funds Management Ltd., and BlackRock Fund Advisors.
vTv Therapeutics Inc (NASDAQ:VTVT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/vtvt"><img src="https://images.fintel.io/us-vtvt-so.png" alt="VTVT / vTv Therapeutics Inc Institutional Ownership"><a>
|SPHERA FUNDS MANAGEMENT LTD.||281,679||281,679||0.00||1,693||1,146||-32.31|
|WELLS FARGO & COMPANY/MN||1,539||1,555||1.04||9||6||-33.33|
|VANGUARD GROUP INC||226,097||293,550||29.83||1,359||1,194||-12.14|
|STATE STREET CORP||111,724||104,241||-6.70||673||424||-37.00|
|FRANKLIN RESOURCES INC||850,100||835,323||-1.74||5,109||3,400||-33.45|
|BlackRock Investment Management, LLC||27,758||27,758||0.00||200||134||-33.00|
|Candriam Luxembourg S.C.A.||90,000||0||-100.00||541||0||-100.00|
|NEW YORK STATE COMMON RETIREMENT FUND||4,300||4,300||0.00||26||18||-30.77|
|UBS Group AG||714||1,000||40.06||4||4||0.00|
|Legal & General Group Plc||888||888||0.00||5||4||-20.00|
|Advisor Group, Inc.||800||1,200||50.00||5||5||0.00|
|PANAGORA ASSET MANAGEMENT INC||5,117||4,860||-5.02||31||20||-35.48|
|Sabby Management, LLC||44,500||0||-100.00||267||0||-100.00|
|Bank of New York Mellon Corp||21,973||21,973||0.00||132||90||-31.82|
|FMR LLC / Fidelity||0||295,838||0||1,204|
|Perigon Wealth Management, LLC||75||75||0.00||0||0|
|JP Morgan Chase & Co||210,215||327,728||55.90||1,263||1,333||5.54|
|DEUTSCHE BANK AG\||16,536||28,284||71.04||99||114||15.15|
|BlackRock Fund Advisors||213,273||245,203||14.97||1,533||1,184||-22.77|
|BALYASNY ASSET MANAGEMENT LLC||24,200||98|
|WALL STREET ASSOCIATES||244,000||164,939||-32.40||1,754||797||-54.56|
|CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM||11,218||11,218||0.00||67||46||-31.34|
|PIPER JAFFRAY COMPANIES||685,995||181,910||-73.48|
|BRONFMAN E.L. ROTHSCHILD, L.P.||29||29||0.00||0||0|
|Renaissance Technologies LLC||55,000||19,800||-64.00||331||81||-75.53|
|Stratos Wealth Partners, LTD.||39||39||0.00||0||0|
|MILLENNIUM MANAGEMENT LLC||62,669||95,031||51.64||377||387||2.65|
|Royce & Associates LLC||225,000||363,000||61.33||1,352||1,477||9.25|
|NORTHERN TRUST CORP||77,026||96,200||24.89||463||391||-15.55|
|BlackRock Advisors LLC||48,892||48,892||0.00||352||236||-32.95|
|Ameritas Investment Partners, Inc.||500||500||0.00||3||2||-33.33|
|GEODE CAPITAL MANAGEMENT, LLC||41,949||43,691||4.15||252||177||-29.76|
|Tower Research Capital LLC (TRC)||1,294||5,817||349.54||8||24||200.00|
|BANK OF AMERICA CORP /DE/||829||541||-34.74||5||2||-60.00|
|BNP PARIBAS ARBITRAGE, SA||1,735||1,528||-11.93||10,427||6,219||-40.36|
|Alyeska Investment Group, L.P.||189,143||53,955||-71.47||1,137||220||-80.65|
|TEACHERS ADVISORS INC||8,421||0||-100.00||51||0||-100.00|
|MASSACHUSETTS FINANCIAL SERVICES CO /MA/||450,892||455,553||1.03||2,710||1,854||-31.59|
|SCHWAB CHARLES INVESTMENT MANAGEMENT INC||12,200||12,200||0.00||74||50||-32.43|
|ROYAL BANK OF CANADA||67||10||-85.07||0||0|
|AMERIPRISE FINANCIAL INC||172,924||0||-100.00||1,039||0||-100.00|
|TIAA CREF INVESTMENT MANAGEMENT LLC||15,064||15,064||0.00||91||61||-32.97|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||2,685||1,186||-55.83||16||5||-68.75|
|Parallax Volatility Advisers, L.P.||1,134||0||-100.00||7||0||-100.00|
|BlackRock Institutional Trust Company, N.A.||91,121||74,280||-18.48||655||359||-45.19|
|J. Goldman & Co LP||26,000||106|
|CAM Group Holding A/S||97,963||399|
|BlackRock Group LTD||32,934||32,934||0.00||237||159||-32.91|
|BRIDGEWAY CAPITAL MANAGEMENT INC||75,000||75,000||0.00||451||305||-32.37|
|AMERICAN INTERNATIONAL GROUP INC||4,778||4,534||-5.11||29||18||-37.93|
|GMT Capital Corp||939,100||3,822|
11h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Both large and small concerns continue to see nothing but failure in the Alzheimer's space despite spending billions on development efforts. (442-11)
China's e-commerce giant Alibaba (NYSE:BABA) will transfer Ali JK Nutritional products into its online healthcare subsidiary, Alibaba Health (HK:0241), in exchange for $1.4 billion of Ali Health stock. Ali JK Nutritional sells medical devices, healthcare products, adult products, and healthcare services on Alibaba's Tmall platform. During the 12 months ending March 31, Ali JK generated $3.2 billion in sales from over 3,300 related merchants. (89-1)
A little more than three months ago we extensively covered Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196. Incidentally in that article we wrote “the last three months have seen gains of more than 230%.” And shareholders would have loved to see the same thing happen in the last three months. But that hasn’t happened. However what has happened is perhaps both more intriguing and interesting at the same time. (58-5)
vTv Therapeutics Inc. (NASDAQ: VTVT) shares saw a massive gain early on Thursday after the firm announced an exclusive licensing agreement with Newsoara Biopharma. This deal is for the rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries. (0-2)
Today's Editor's Notes reviews five short ideas that each have a way of keeping it simple. (220-14)
as of ET